Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Pramipexole Dihydrochloride

FDA-approved product (tablet, oral), marketed as Mirapex, Mirapex Er, Pramipexole Dihydrochloride.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Pramipexole Dihydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Parkinson disease
  • Restless legs syndrome

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Dopamine agonists
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli41.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae15.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis25.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Pramipexole Dihydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-5.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-5.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Pramipexole Dihydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study to Observe the Effect of Mirapex ER® Once-daily (QD) Versus Twice-daily (BID)

    NCT01515774 · start 2011-09

    Registered record
    Registry ID
    NCT01515774
    Conditions
    Parkinson's Disease
    Interventions
    Mirapex ER
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2011-09
    Completion
    2012-10
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease
    InterventionMirapex ER
    PhasePhase 4
    Registry statusUnknown

  • Safety Study of R(+)Pramipexole to Treat Early Alzheimer's Disease

    NCT01388478 · start 2011-07

    Registered record
    Registry ID
    NCT01388478
    Conditions
    Alzheimer's Disease
    Interventions
    R-pramipexole
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-07
    Completion
    2014-04
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer's Disease
    InterventionR-pramipexole
    PhasePhase 2
    Registry statusCompleted

  • a PMS on Safety Profile of Pramipexole in Chinese Parkinson Disease Patients

    NCT01361009 · start 2011-05

    Registered record
    Registry ID
    NCT01361009
    Conditions
    Parkinson Disease
    Interventions
    pramipexole
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2011-05
    Completion
    2012-02
    Enrolment
    2,017

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    Interventionpramipexole
    PhaseNot recorded
    Registry statusCompleted

  • Minocycline, Acetylsalicylic Acid or Pramipexole vs Placebo in Patients With Schizophrenia or Schizoaffective Disorder

    NCT01320982 · start 2011-03

    Registered record
    Registry ID
    NCT01320982
    Conditions
    Schizophrenia; Schizoaffective Disorder
    Interventions
    minocycline; pramipexole; acetylsalicylic acid; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2011-03
    Completion
    2012-07
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizoaffective Disorder
    Interventionminocycline; pramipexole; acetylsalicylic acid; placebo
    PhasePhase 3
    Registry statusUnknown

  • Pramipexole Extended Release Versus Pramipexole Immediate Release for 18 Weeks in Chinese Parkinson's Disease (PD) Patients

    NCT01191944 · start 2010-08

    Registered record
    Registry ID
    NCT01191944
    Conditions
    Parkinson Disease
    Interventions
    pramipexole immediate release tablet; pramipexole extended release tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-08
    Completion
    2012-01
    Enrolment
    475

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    Interventionpramipexole immediate release tablet; pramipexole extended release tablet
    PhasePhase 3
    Registry statusCompleted

  • Influence of Piribedil (Clarium®) on Vigilance and Cognitive Function in Patients With Parkinson's Disease Compared to Other Non-Ergot Dopamine Agonists

    NCT01007864 · start 2010-01

    Registered record
    Registry ID
    NCT01007864
    Conditions
    Idiopathic Parkinson's Disease
    Interventions
    piribedil; pramipexole or ropinirole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-01
    Completion
    2011-12
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIdiopathic Parkinson's Disease
    Interventionpiribedil; pramipexole or ropinirole
    PhasePhase 3
    Registry statusCompleted

  • Assessment of the Safety and Efficacy of Pramipexole Extended Release in Patients With Parkinson's Disease in Routine Clinical Practice

    NCT01061567 · start 2009-11

    Registered record
    Registry ID
    NCT01061567
    Conditions
    Parkinson's Disease
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2009-11
    Completion
    2013-06
    Enrolment
    1,814

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Study to Compare the Effect of Ropinirole Prolonged Release Once-daily Versus Twice-daily

    NCT00986245 · start 2009-09

    Registered record
    Registry ID
    NCT00986245
    Conditions
    Parkinson Disease
    Interventions
    Ropinirole Prolonged release
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-09
    Completion
    2010-12
    Enrolment
    82

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionRopinirole Prolonged release
    PhasePhase 4
    Registry statusCompleted

  • Evaluation of the Tolerance and Acceptability of Rasagiline in the Treatment of Early-stage Parkinson's Disease

    NCT01048229 · start 2008-10

    Registered record
    Registry ID
    NCT01048229
    Conditions
    Early-stage Parkinson's Disease
    Interventions
    Rasagiline; Pramipexole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2008-10
    Completion
    2010-03
    Enrolment
    112

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEarly-stage Parkinson's Disease
    InterventionRasagiline; Pramipexole
    PhasePhase 4
    Registry statusTerminated

  • Pramipexole ER vs. Placebo in Fibromyalgia

    NCT00689052 · start 2008-07

    Registered record
    Registry ID
    NCT00689052
    Conditions
    Fibromyalgia
    Interventions
    pramipexole ER; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2008-07
    Completion
    Not recorded
    Enrolment
    61

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFibromyalgia
    Interventionpramipexole ER; placebo
    PhasePhase 2
    Registry statusTerminated

  • Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome

    NCT00681863 · start 2008-05

    Registered record
    Registry ID
    NCT00681863
    Conditions
    Tourette Syndrome
    Interventions
    pramipexole 0.125 mg BID; pramipexole 0.0625 mg QD; pramipexole 0.125 mg TID; pramipexole 0.25 mg BID; pramipexole 0.0625 mg BID
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2008-05
    Completion
    Not recorded
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTourette Syndrome
    Interventionpramipexole 0.125 mg BID; pramipexole 0.0625 mg QD; pramipexole 0.125 mg TID; pramipexole 0.25 mg BID +1 more
    PhasePhase 3
    Registry statusTerminated

  • Observational Study in Parkinson's Disease of the Primary Care Population of Patients Treated With Pramipexole

    NCT02236728 · start 2008-02

    Registered record
    Registry ID
    NCT02236728
    Conditions
    Parkinson Disease
    Interventions
    Pramipexole
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2008-02
    Completion
    Not recorded
    Enrolment
    497

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionPramipexole
    PhaseNot recorded
    Registry statusCompleted

  • Pramipexole and the Risk of Serious Adverse Events

    NCT07382960 · start 2008-01-01

    Registered record
    Registry ID
    NCT07382960
    Conditions
    Older Adults (65 Years and Older); Chronic Kidney Disease (CKD)
    Interventions
    Pramipexole
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2008-01-01
    Completion
    2028-12-31
    Enrolment
    1,100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOlder Adults (65 Years and Older); Chronic Kidney Disease (CKD)
    InterventionPramipexole
    PhaseNot recorded
    Registry statusActive not recruiting

  • Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).

    NCT00601523 · start 2008-01

    Registered record
    Registry ID
    NCT00601523
    Conditions
    Parkinson Disease
    Interventions
    Placebo; Pramipexole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-01
    Completion
    Not recorded
    Enrolment
    511

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionPlacebo; Pramipexole
    PhasePhase 3
    Registry statusCompleted

  • Safety and Effect of Mirapex(Pramipexole) Tablet Among Korean RLS

    NCT01170091 · start 2007-12

    Registered record
    Registry ID
    NCT01170091
    Conditions
    Restless Legs Syndrome
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2007-12
    Completion
    Not recorded
    Enrolment
    651

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRestless Legs Syndrome
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted